Drug Manufacturers - Specialty & Generic · Healthcare
Board Member
2017-01-01–present
Equibles does not estimate personal net worth.
Get an email with a short summary when Green Thumb Industries Inc. publishes a filing, an earnings call transcript or a press release.
Get GTBIF alertsAnthony Georgiadis is recorded as Board Member at Green Thumb Industries Inc. (GTBIF) since January 1, 2017. The newest filing on record that lists Anthony Georgiadis as Board Member at Green Thumb Industries Inc. (GTBIF) is dated April 27, 2026. Green Thumb Industries Inc. reported in an 8-K filed June 12, 2025 that Anthony Georgiadis was appointed director, effective June 11, 2025. Green Thumb Industries Inc. reported in an 8-K filed December 13, 2022 that Anthony Georgiadis was appointed President, effective January 1, 2023. The proxy statement of Green Thumb Industries Inc. reports total compensation of $2,930,970 for Anthony Georgiadis in fiscal 2025, including a base salary of $350,318. Disclosed compensation is on record for 8 fiscal years. Anthony Georgiadis has spoken on 4 earnings calls across 1 company, most recently for Green Thumb Industries Inc. on August 4, 2026. Green Thumb Industries Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Green Thumb Industries Inc. includes Benjamin Kovler (CEO and Board Member), Mathew Faulkner (CFO and Chief Accounting Officer), Matt Faulkner (CFO) and 7 others.
“Elected the seven director nominees named in the Company’s 2025 Proxy Statement to serve as directors until the Company’s 2026 annual general meeting of shareholders or the date on which they otherwise cease to hold office under the British Columbia Corporations Act or under the Company’s articles”
“the Company announced that Anthony Georgiadis, age 44, the Company's current Chief Financial Officer and a member of its Board, had been promoted to the position of President effective January 1, 2023”
“The company generated $307 million of revenue and $84 million of normalized EBITDA, representing 5% year-over-year top-line growth. Unpacking the results, retail revenue grew just under 4% versus the prior year period, with strong contributions from Minnesota, Connecticut, and Florida.”
“We invested $19 million in capital during the quarter. Retail investments included store relocations, renovations, and openings in Pennsylvania, Minnesota, Ohio, and Florida.”
“In the first quarter, we invested $30 million in CapEx, opening new stores in Florida and Nevada, and continuing to invest into our wholesale footprint in New Jersey and Connecticut.”
2023-01-01–present
2017-01-01–present
Last confirmed April 27, 2026
Start not stated–2022-05-02
Last confirmed by a filing; no departure on record
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member
2017-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Green Thumb Industries Inc. (GTBIF) | President and Director | $350,318 | $2,930,970 |
| 2024 | Green Thumb Industries Inc. (GTBIF) | President and Director | $360,014 | $10,378,419 |
| 2023 | Green Thumb Industries Inc. (GTBIF) | President and Director | $360,014 | $1,778,267 |
| 2022 | Green Thumb Industries Inc. (GTBIF) | President and Director | $360,014 | $1,970,222 |
| 2021 | Green Thumb Industries Inc. (GTBIF) | Chief Financial Officer and Director | $360,002 | $1,394,492 |
| 2020 | Green Thumb Industries Inc. (GTBIF) | Chief Financial Officer and Director | $322,500 | $1,335,996 |
| 2019 | Green Thumb Industries Inc. (GTBIF) | Chief Financial Officer and Director | $297,500 | $3,237,378 |
| 2018 | Green Thumb Industries Inc. (GTBIF) | Chief Financial Officer and Director | $250,000 | $1,503,877 |